News for Abbott Laboratories - Google Finance

How Will Q1 Results Impact Abbott Laboratories' Stock?

Thu, 23 May 2013 19:36:57 GMT

How Will Q1 Results Impact Abbott Laboratories' Stock?
DailyFinance - May 23, 2013

Nutrition stands out as the shining star for Abbott Laboratories and perhaps the primary reason for continued interest in the stock.

Abbott Laboratories: Undervalued Potential - Seeking Alpha

Abbott Laboratories Stock Checkup for May

Thu, 23 May 2013 19:36:50 GMT

Abbott Laboratories Stock Checkup for May
DailyFinance - May 23, 2013

How does Abbott Laboratories stock fare against its peers in health care? Let's use the SPDR Health Care Select ETF as a proxy to represent the health-care industry as a whole.

Abbott Laboratories lifted to buy at Goldman Sachs

Mon, 20 May 2013 08:04:13 GMT

Abbott Laboratories lifted to buy at Goldman Sachs
MarketWatch - May 20, 2013

Abbott Laboratories lifted to buy at Goldman Sachs. 0 Comments. Tweet. new. Portfolio Relevance. LEARN MORE. Want to see how this story relates to your portfolio?

July Options Now Available For Abbott Laboratories (ABT)

Mon, 20 May 2013 17:25:45 GMT

July Options Now Available For Abbott Laboratories (ABT)
Forbes - May 20, 2013

Investors in Abbott Laboratories Abbott Laboratories (NYSE: ABT) saw new options begin trading today, for the July expiration.

Do Hedge Funds and Insiders Love Abbott Laboratories (ABT)?

Thu, 23 May 2013 19:59:31 GMT

Do Hedge Funds and Insiders Love Abbott Laboratories (ABT)?
Insider Monkey (blog) - May 23, 2013

Judging by the fact that Abbott Laboratories (NYSE:ABT) has experienced declining sentiment from the entirety of the hedge funds we track, logic holds that there is a sect of fund managers that decided to sell off their full holdings in Q1.

UPDATE: Goldman Sachs Upgrades Abbott Laboratories; Growth Is Poised To ...

Mon, 20 May 2013 14:48:21 GMT

UPDATE: Goldman Sachs Upgrades Abbott Laboratories; Growth Is Poised To ...
Benzinga - May 20, 2013

In a report published Sunday, Goldman Sachs analyst David H. Roman upgraded the rating on Abbott Laboratories (NYSE: ABT) from Neutral to Buy and raised the price target on the company from $38.00 to $44.00.

Abbott Laboratories (NYSE:ABT) Raised To Purchase at Goldman Sachs - ABT ... - Galaxy Stocks
Equities Research Analysts' Upgrades for May, 20th (ABT, ACN, DANG, IBKC ... - Zolmax

Jury orders Abbott Labs to pay $2 million in Humira suit

Sat, 11 May 2013 03:00:26 GMT

Jury orders Abbott Labs to pay $2 million in Humira suit
Chicago Business Journal - May 11, 2013

The jury entered a verdict in favor of plaintiff Milton Tietz on behalf of his wife, Delores Tietz and found Abbott Park-based Abbott Labs (NYSE: ABT) negligent for not taking reasonable measures to alert doctors about the side-effect risk of ...

Perdue Kidd & Vickery Wins First Humira Trial - Abbott Laboratories To Pay ... - PR Newswire (press release)
Abbott, AbbVie Hit With $2.2M Verdict In Humira Suit - Law360 (subscription)

Goldman Sachs Upgrades Abbott Labs to “Buy;” 20% Upside (ABT)

Mon, 20 May 2013 13:38:27 GMT

Goldman Sachs Upgrades Abbott Labs to “Buy;” 20% Upside (ABT)
Dividend.com (blog) - May 20, 2013

Goldman Sachs analysts see Abbott Laboratories (ABT ) as a fast growing company with the potential to expand its margins. As such, the analysts upgraded the pharmaceutical company on Monday.

Abbott Laboratories Stock Is Half What It Used to Be

Tue, 30 Apr 2013 18:30:31 GMT

Abbott Laboratories Stock Is Half What It Used to Be
Motley Fool - Apr 30, 2013

Abbott Laboratories stock hit a high in October of last year of 72.47, but when the new year hit, the company split in two, spinning its drug assets into AbbVie (NYSE: ABBV ) .

Abbott, AbbVie seek investors' love - Crain's Chicago Business
Humira Was A Factor In Widespread Infection, Doctor Testifies - Law360 (subscription)

Pressure Mounts to Remove GMOs from Infant Formula; Abbott Laboratories ...

Fri, 03 May 2013 14:46:20 GMT

Pressure Mounts to Remove GMOs from Infant Formula; Abbott Laboratories ...
Truth-Out - May 3, 2013

Cornucopia, WI -- Shareholders of Abbott Laboratories will vote on whether the manufacturer of Similac, a leading brand of infant formula, should adopt a policy of sourcing ingredients that have not been genetically engineered.